<DOC>
	<DOCNO>NCT00363714</DOCNO>
	<brief_summary>The purpose study assess safety tolerability dose-limiting toxicity single intravitreal injection Sirna-027 ( AGN211745 ) assess anatomical change retina , change CNV , change visual acuity . Escalation next dose cohort complete follow minimum 2 week follow-up . Patients monitor intensively three month , followed-up safety 24 month post-injection .</brief_summary>
	<brief_title>A Dose Escalation Trial Intravitreal Injection Sirna-027 Patients With Subfoveal Choroidal Neovascularization ( CNV ) Secondary Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>Active AMD Subfoveal CNV ( classic and/or occult CNV ) CNV lesion thickness &gt; /= 250um OCT assessment Visual acuity study eye &lt; /= 20/100 bad 20/800 Not eligible refused standard treatment Females childbearing potential Other cause CNV include pathologic myopia , ocular histoplasmosis syndrome , angioid streak , choroidal rupture multifocal choroiditis Any intraocular surgery treatment AMD Visudyne within 3 month study entry CNV lesion &gt; /= 12 MPS disc area</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>